Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms

Circulation

Volumn 117, Issue 17, 2008, Pages 2211-2223

  Nakata, Sei ^a   Tsutsui, Masato ^a   Shimokawa, Hiroaki ^b   Suda, Osamu ^a   Morishita, Tsuyoshi ^a   Shibata, Kiyoko ^a   Yatera, Yasuko ^a   Sabanai, Ken ^a   Tanimoto, Akihide ^a   Nagasaki, Machiko ^a   Tasaki, Hiromi ^a   Sasaguri, Yasuyuki ^a   Nakashima, Yasuhide ^a   Otsuji, Yutaka ^a   Yanagihara, Nobuyuki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin; Arteriosclerosis; Myocardial infarction; Nitric oxide synthase

Indexed keywords

ADIPONECTIN; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEURONAL NITRIC OXIDE SYNTHASE; OLMESARTAN; RENIN; TRIACYLGLYCEROL; NOS1 PROTEIN, MOUSE; NOS2 PROTEIN, MOUSE; NOS3 PROTEIN, MOUSE;

ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOSCLEROSIS; ARTICLE; BLOOD PRESSURE REGULATION; CAUSE OF DEATH; CEREBRAL ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ECG ABNORMALITY; ENZYME DEFICIENCY; EPIDIDYMIS FAT; GLOMERULOPATHY; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPROTEINEMIA; IMPAIRED GLUCOSE TOLERANCE; INTRAABDOMINAL FAT; KIDNEY TUBULE DISORDER; MALE; MEAN ARTERIAL PRESSURE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; VASODILATATION; WHITE ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; CORONARY ARTERY DISEASE; GENETICS; GLUCOSE INTOLERANCE; HOMEOSTASIS; METABOLISM; MORTALITY; MOUSE MUTANT; PHYSIOLOGY; RISK FACTOR; SUDDEN DEATH;

ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; HOMEOSTASIS; HYPERTENSION; INTRA-ABDOMINAL FAT; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; OBESITY; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 44049102229     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.742692     Document Type: Article

References (44)

1. Bredt DS, Snyder SH. Nitric oxide: a physiological messenger molecule. Annu Rev Biochem. 1994;63:175-195.
2. Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol. 1984;24:175-197.
3. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30:535-560.
4. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
5. Murad F. What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle? Circulation. 1997;95:1101-1103.
6. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999;31:23-37.
7. G-nitro-L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ Res. 1993;72:387-395.
8. Heim KF, Thomas G, Ramwell PW. Effect of substituted arginine compounds on superoxide production in the rabbit aorta. J Pharmacol Exp Ther. 1991;257:1130-1135.
9. Peterson DA, Peterson DC, Archer S, Weir EK. The nonspecificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun. 1992;187:797-801.
10. w-nitro-L-arginine benzyl ester, a potent irreversible inhibitor of endothelium dependent relaxation. Biochem Biophys Res Commun. 1991;179:1677-1682.
11. - -nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation. 2002;106:1729-1735.
12. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24:1682-1688.
13. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, Thorens B, Scherrer U. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly. 2003;133:360-363.
14. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104:342-345.
15. Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998;101:1225-1232.
16. Son H, Hawkins RD, Martin K, Kiebler M, Huang PL, Fishman MC, Kandel ER. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell. 1996;87: 1015-1023.
17. Huang A, Sun D, Shesely EG, Levee EM, Koller A, Kaley G. Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO mice. Am J Physiol Heart Circ Physiol. 2002;282:H429-H436.
18. Lamping KG, Nuno DW, Shesely EG, Maeda N, Faraci FM. Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol. 2000;279: H1906-H1912.
19. Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Tasaki H, Suda O, Nakata S, Tanimoto A, Wang KY, Ueta Y, Sasaguri Y, Nakashima Y, Yanagihara N. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci U S A. 2005;102: 10616-10621.
20. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002;43:805-814.
21. Winzell MS, Pacini G, Wollheim CB, Ahren B. Beta-cell-targeted expression of a dominant-negative mutant of hepatocyte nuclear factor-1alpha in mice: diabetes model with beta-cell dysfunction partially rescued by nonglucose secretagogues. Diabetes. 2004;53:S92-S96.
22. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
23. Nakamura H, Inoue T, Arakawa N, Shimizu Y, Yoshigae Y, Fujimori I, Shimakawa E, Toyoshi T, Yokoyama T. Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models. Eur J Pharmacol. 2005;512:239-246.
24. Kurioka S, Koshimura K, Murakami Y, Nishiki M, Kato Y. Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr J. 2000;47:77-81.
25. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension. 1997;30:405-408.
26. Sun YX, Hu SJ, Zhang XH, Sun J, Zhu CH, Zhang ZJ. Plasma levels of vWF and NO in patients with metabolic syndrome and their relationship with metabolic disorders. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006; 35:315-318.
27. Tanaka S, Yashiro A, Nakashima Y, Nanri H, Ikeda M, Kuroiwa A. Plasma nitrite/nitrate level is inversely correlated with plasma lowdensity lipoprotein cholesterol level. Clin Cardiol. 1997;20:361-365.
28. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A, Colombo A. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003;108:2074-2081.
29. Cooke JP. ADMA: its role in vascular disease. Vasc Med. 2005;10: S11-S17.
30. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the "Yin-Yang" effect, a Chinese concept for a worldwide pandemic. Swiss Med Wkly. 2006;136:103-113.
31. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M, Krieger M. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res. 2002;90:270-276.
32. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoEdeficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
33. Antman EM, Braunwald E. ST-elevation myocardial infarction: pathology, pathophysiology, and clinical features. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005:1141-1166.
34. Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation. 1989;80:1-9.
35. Laine P, Kaartinen M, Penttila A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation. 1999;99: 361-369.
36. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care. 2005;28:2745-2749.
37. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium; International Diabetes Federation; 2005.
38. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777-780.
39. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29-33.
40. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol. 2005;25:915-922.
41. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther. 2002;16:149-160.
42. Ernsberger P, Koletsky RJ. Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:245-258.
43. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation. 2004;110: 1507-1512.
44. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-1792.